We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exelixis (EXEL) Rallies 22.4% YTD: What to Expect Ahead?
Read MoreHide Full Article
Shares of Exelixis, Inc. (EXEL - Free Report) have rallied 22.4% in the year so far, outperforming 14.6% growth registered by the industry.
The company received a major boost with the approval of a tablet formulation of cabozantinib, Cabometyx, which was approved in the United States in April 2016 for the treatment of patients with advanced renal cell carcinoma (RCC), who have received prior anti-angiogenic therapy.
Since the drug is now approved for first-line RCC as well, Exelixis can now target the entire patient population suffering from the disease in the United States. Cabometyx continues to maintain its market leading position in RCC. The drug held 34% market share at the end of the fourth quarter, driven by its broad label for advanced RCC and the recent NCCN update as the preferred TKI for the majority of both previously untreated and refractory RCC patients. The company experienced a 10% increase in Cabometyx’s prescriber base compared with that in the third quarter.
Exelixis is evaluating cabozantinib in a broad development program, comprising more than 45 clinical studies across multiple indications. In January 2019, the FDA also approved Cabometyx for hepatocellular carcinoma (HCC). Per estimates, more than 40,000 patients are diagnosed with liver cancer, resulting in approximately 29,000 deaths each year in the United States. Sales should get a boost from this label expansion, given the market potential.
Exelixis also has collaboration agreements with Bristol-Myers Squibb (BMY - Free Report) and Roche (RHHBY - Free Report) to evaluate cabozantinib in combination with immunotherapy agents.
While the RCC market holds immense potential, competition is stiff. The approval of Opdivo and Yervoy for the treatment of poor and intermediate risk first-line RCC has increased competition for Cabometyx.
The FDA recently granted priority review to Merck’s (MRK - Free Report) sBLA for Keytruda in combination with Inlyta for the first-line treatment of patients with advanced RCC, based on the results of KEYNOTE-426. The agency has set a target action date of Jun 20, 2019.
Hence, we expect investors to focus on Cabometyx’s performance in 2019, which is expected to be backed by a broad label.
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
Image: Bigstock
Exelixis (EXEL) Rallies 22.4% YTD: What to Expect Ahead?
Shares of Exelixis, Inc. (EXEL - Free Report) have rallied 22.4% in the year so far, outperforming 14.6% growth registered by the industry.
The company received a major boost with the approval of a tablet formulation of cabozantinib, Cabometyx, which was approved in the United States in April 2016 for the treatment of patients with advanced renal cell carcinoma (RCC), who have received prior anti-angiogenic therapy.
Since the drug is now approved for first-line RCC as well, Exelixis can now target the entire patient population suffering from the disease in the United States. Cabometyx continues to maintain its market leading position in RCC. The drug held 34% market share at the end of the fourth quarter, driven by its broad label for advanced RCC and the recent NCCN update as the preferred TKI for the majority of both previously untreated and refractory RCC patients. The company experienced a 10% increase in Cabometyx’s prescriber base compared with that in the third quarter.
Exelixis is evaluating cabozantinib in a broad development program, comprising more than 45 clinical studies across multiple indications. In January 2019, the FDA also approved Cabometyx for hepatocellular carcinoma (HCC). Per estimates, more than 40,000 patients are diagnosed with liver cancer, resulting in approximately 29,000 deaths each year in the United States. Sales should get a boost from this label expansion, given the market potential.
Exelixis also has collaboration agreements with Bristol-Myers Squibb (BMY - Free Report) and Roche (RHHBY - Free Report) to evaluate cabozantinib in combination with immunotherapy agents.
While the RCC market holds immense potential, competition is stiff. The approval of Opdivo and Yervoy for the treatment of poor and intermediate risk first-line RCC has increased competition for Cabometyx.
The FDA recently granted priority review to Merck’s (MRK - Free Report) sBLA for Keytruda in combination with Inlyta for the first-line treatment of patients with advanced RCC, based on the results of KEYNOTE-426. The agency has set a target action date of Jun 20, 2019.
Hence, we expect investors to focus on Cabometyx’s performance in 2019, which is expected to be backed by a broad label.
Zacks Rank
Exelixis currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>